Company profile
Covis Pharma
Privately held: no public share price
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Aclidinium bromide(Tudorza Pressair) | Approved | Muscarinic acetylcholine receptor (M3)Small molecule | Chronic Obstructive Pulmonary Disease |
Aclidinium bromide/formoterol fumarate(Duaklir Pressair) | Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.